Results now emerge from a preclinical trial of a heat-shock protein inhibitor in a mouse model of neurodegenerative disease. The data indicate that targeting a misfolded protein for degradation may be a useful therapeutic strategy (pages 1088–1095).
- Albert R La Spada
- Patrick Weydt
